药物信息为VIBATIV (telavancin) for injection, for intravenous useInitial U.S. Approval: 2009To reduce the development of drug-resistant bacteria and maintain the effectiveness of VIBATIV and other antibacterial drugs, VIBATIV should be used only to treat or prevent infections that are proven or strongly suspected to (Astellas Pharma US Inc.): WARNING: FETAL RISK
- WARNING: FETAL RISK
- 1 INDICATIONS AND USAGE
- 3 DOSAGE FORMS AND STRENGTHS
- 4 CONTRAINDICATIONS
- 6 ADVERSE REACTIONS
- 10 OVERDOSAGE
- 11 DESCRIPTION
- 15 REFERENCES
- 16 HOW SUPPLIED/STORAGE AND HANDLING
- 17 PATIENT COUNSELING INFORMATION
- PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 250 MG/VIAL LABEL
- PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 250 MG/VIAL CARTON
- PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 750 MG/VIAL LABEL
- PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 750 MG/VIAL CARTON
- 外部链接相关的VIBATIV (telavancin) for injection, for intravenous useInitial U.S. Approval: 2009To reduce the development of drug-resistant bacteria and maintain the effectiveness of VIBATIV and other antibacterial drugs, VIBATIV should be used only to treat or prevent infections that are proven or strongly suspected to (Astellas Pharma US Inc.)
- Women of childbearing potential should have a serum pregnancy test prior to administration of VIBATIV
- Avoid use of VIBATIV during pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus
- Adverse developmental outcomes observed in 3 animal species at clinically relevant doses raise concerns about potential adverse developmental outcomes in humans [see Warnings and Precautions (5.1), Use in Specific Populations (8.1)]
- Drug Information Provided by National Library of Medicine (NLM).
这个站点被设计主要作为提示系统供合格的医师和其他医疗专家使用。 通过使用这个站点您了解并且接受DiagnosisPro.com不会使用作为一个诊断决策系统，并且不能使用做一个临床诊断或替换或者否决一位被准许的医疗保健专家的评断或临床诊断 (充分的使用条款). 我们遵循健康网络基金会的 医学和健康网站的行为准则. 点击这里核实
© 2012 MedTech USA, Inc. (最后更新在05/25/12)
